Patrick Kilhenny, MD
Neurology · Virginia Beach, VANPI 1457466351
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,565 of the $102,267 with a category attached, or 75.8%. 39 manufacturers reported payments, led by AbbVie at 41.9% of the total. Reporting peaked in 2022 at $38,464 and has fallen 62.7% since, to $14,349 in 2025. Among neurology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,580 payments — averaging $64.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Mallinckrodt Hospital Products Inc.$33K
- Biohaven Pharmaceuticals, Inc.$5K
- Biogen$5K
- Biohaven Pharmaceutical Holding Company Ltd.$4K
- Novartis$2K
- plus $10K from 33 others
What the payments were for
- Speaking & faculty fees$77,56576%
- Travel & lodging$2,6373%
- Food & beverage$21,02821%
- Education$1,0381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,267 in reported general payments places this provider in the 90th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 43 | $367,335 |
| Kesimpta PenOfatumumab | 21 | $227,141 |
| QuliptaAtogepant | 31 | $56,096 |
| UbrelvyUbrogepant | 34 | $51,485 |
| Nurtec OdtRimegepant Sulfate | 31 | $49,545 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 16 | $24,109 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $22,631 |
| Emgality PenGalcanezumab-Gnlm | 20 | $19,696 |
| ReyvowLasmiditan Succinate | 19 | $15,666 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 29 | $13,912 |
| Pyridostigmine Bromide | 168 | $12,185 |
| Memantine Hcl | 154 | $4,516 |
| Memantine Hcl ErMemantine Hcl | 21 | $2,593 |
| Levetiracetam ErLevetiracetam | 20 | $2,530 |
| Primidone | 50 | $1,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $5,039 | $367,33543 claims |
| AbbVieQulipta, Ubrelvy | $42,880 | $107,58165 claims |
| PfizerNurtec Odt | $902 | $49,54531 claims |
| Lilly USA, LLCReyvow | $489 | $15,66619 claims |
| Upsher-smith Laboratories LLCTopiramate | $152 | $1,63173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 neurology providers in Virginia.
Other neurology in Virginia Beach
- Michelle BetzVirginia Beach$250K
- Amelito B MalapiraVirginia Beach$227K
- Ramsey FalconerAlexandria$2M
- Robert ShinCharlottesville$1.7M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
- Jill CramerChristiansburg$598K
- Rahul DaveFairfax$540K
- Daniel HardyRichmond$382K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.